Top Banner
Therapeutic Vaccines for Alzheimer’s — Are We Close Enough? Read Full Report
8

Therapeutic Vaccines for Alzheimer’s — Are We Close Enough?

Apr 11, 2017

Download

Health & Medicine

Aranca
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Page 1: Therapeutic Vaccines for Alzheimer’s — Are We Close Enough?

Therapeutic Vaccines for

Alzheimer’s — Are We Close

Enough?

Read Full Report

Page 2: Therapeutic Vaccines for Alzheimer’s — Are We Close Enough?

Alzheimer's disease (AD) a major

cause of Dementia today across the

world

Read Full Report

Page 3: Therapeutic Vaccines for Alzheimer’s — Are We Close Enough?

By 2030 nearly 63% of

Alzheimer cases will be in low

or middle-income countries

Read Full Report

Page 4: Therapeutic Vaccines for Alzheimer’s — Are We Close Enough?

From 1998-2014 only 4 drugs

have been approved by the FDA

leading to 1:30 ratio of successful

therapy

Read Full Report

Page 5: Therapeutic Vaccines for Alzheimer’s — Are We Close Enough?

The cost of Alzheimer treatment

could reduce by $367 billion

(by 2050)

Read Full Report

Page 6: Therapeutic Vaccines for Alzheimer’s — Are We Close Enough?

Global market for Alzheimer’s

treatment expected to grow at a CAGR

of 10.5% from $4.9 billion in 2013 to

$13.3 billion by 2023

Read Full Report

Page 7: Therapeutic Vaccines for Alzheimer’s — Are We Close Enough?

The United States, accounts for nearly

40% of AD therapeutics market share

and tops in terms of innovator

geography

Read Full Report

Page 8: Therapeutic Vaccines for Alzheimer’s — Are We Close Enough?

Could a vaccine for Alzheimer’s be a reality any sooner?

Find more on Alzheimer Therapy Market Challenges from Aranca’s Technology

Intelligence & IP Research Experts.

Read Full Report Explore our work